Yoran Hummel

Ph.D. | Echo enthusiast | researcher | curious by nature | enjoying the small things in life | dad | president of @Us2_ai

[Us2 @us2_ai]

Dr. Jasper Tromp led an economic evaluation of AI-assisted LVEF assessment in Singapore. 𝐓𝐡𝐞 𝐜𝐨𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧: 𝐀𝐈-𝐩𝐨𝐰𝐞𝐫𝐞𝐝 𝐩𝐨𝐢𝐧𝐭-𝐨𝐟-𝐜𝐚𝐫𝐞 𝐮𝐥𝐭𝐫𝐚𝐬𝐨𝐮𝐧𝐝 𝐢𝐬 𝐧𝐨𝐭 𝐣𝐮𝐬𝐭 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞 — 𝐢𝐭'𝐬 𝐚 💰𝐜𝐨𝐬𝐭-𝐬𝐚𝐯𝐢𝐧𝐠💰 𝐩𝐚𝐭𝐡 𝐟𝐨𝐫 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐜𝐚𝐫𝐞.

Published in ESC Heart Failure, the study looked at the cost of AI-assisted LVEF assessment using https://t.co/LR5so3R0R3, performed by novices, versus standard sonographer-led echocardiography in Singapore.

Same diagnostic accuracy. Significantly lower cost.

Dr. Tromp, Assistant Professor at the Saw Swee Hock School of Public Health, National University of Singapore, shares what this means for healthcare systems where echocardiographic capacity is limited and heart failure is on the rise.

We are proud to have https://t.co/LR5so3R0R3 as the AI echo software featured in this work!

🔗 Full study: https://t.co/1yTfLizUd7

[Us2 @us2_ai]

𝐓����𝐢𝐬 𝐢𝐬 𝐔𝐬2.𝐚𝐢. 𝐖𝐡𝐨 𝐰𝐞 𝐚𝐫𝐞, 𝐰𝐡𝐲 𝐰𝐞 𝐛𝐮𝐢𝐥𝐭 𝐢𝐭, 𝐚𝐧𝐝 𝐰𝐡𝐚𝐭 𝐢𝐭 𝐦𝐞𝐚𝐧𝐬 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐞𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲.

At the heart of everything we do is a simple mission: make echocardiography analysis more accurate, more efficient and more accessible for clinicians and patients around the world.

"The gain that you get, the reduction of error in reducing variability of day to day measurements doesn't even speak to the other benefits of using an AI echo platform like this, and the efficiency gains in throughput in a lab, is incredibly amazing." – Dr. Ken Stein

If you are new to https://t.co/LR5so3R0R3 or just curious about what we are building, this is the best place to start.
👉 Book a demo at https://t.co/yLoT3CRG8w

[Us2 @us2_ai]

🤝 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐨𝐮𝐫 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬!

Did you know https://t.co/LR5so3Qt1v is vendor-neutral? We are partnered with leading OEM and device companies, integrated into AI platforms and PACS systems, and supported by distributors across the globe.

Because AI echo shouldn't be locked into one device, one platform or one workflow. It should work wherever clinicians need it.

Explore the full list of partners at the link below.

🔗 https://t.co/gLr5s6G5kr

[Yoran Hummel @__YmH_]

Do the math … 🦾🫀

[Us2 @us2_ai]

➕The AI-ECHO RCT just proved what many suspected.

AI echo doesn't just help. It elevates the echo workflow.

Hear from Dr. Kagiyama on his experience with the https://t.co/m6D3AknwU3 software

🔗 Full paper: https://t.co/xOQk5WvZK0

[Us2 @us2_ai]

1 𝐢𝐧 4 𝐝𝐢𝐚𝐛𝐞𝐭𝐢𝐜 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐡𝐚𝐝 𝐮𝐧𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐞𝐝 𝐡𝐞𝐚𝐫𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞. 𝐌��𝐬𝐭 𝐡𝐚𝐝 𝐧𝐨 𝐢𝐝𝐞𝐚. ‼️

https://t.co/LR5so3Qt1v is proud to be a partner in the landmark TARTAN-HF trial which showed that a widely available NT-proBNP blood test, followed by an echo scan, changed everything.

✅ 1 in 4 screened patients diagnosed compared to 1% in usual care.
✅ 55% reduction in hospitalisation or death.

The evidence is here. Now health systems need to act.

[Us2 @us2_ai]

😊 𝐌𝐞𝐞𝐭 𝐭𝐡𝐞 𝐭𝐞𝐚𝐦 𝐛𝐞𝐡𝐢𝐧𝐝 𝐔𝐬2.𝐚𝐢 👋

When you reach out to https://t.co/LR5so3R0R3, these are the people you'll hear from. A small but mighty global sales team, passionate about bringing AI-powered echocardiography to clinicians and institutions around the world.

In the video you'll meet:
🌏 Daniel Ishak — Asia-Pacific & Middle East
🌍 Nathan Simcox — Europe
🌎 Seth Koeppel — North & South America

And while he couldn't make it on camera this time, rounding out the Americas team is the one and only Dave Ladd.

Whether you're exploring AI echo for the first time or ready to bring https://t.co/LR5so3R0R3 into your institution, these are your people.

Don't hesitate to reach out directly or drop a comment below and we'll get you connected.

[Us2 @us2_ai]

4 weeks. That's all it took for Bordeaux University Hospital to go fully live with AI echo.

894 echos. 31 parameters. ICC up to 0.97.

Peer-reviewed. GDPR compliant. No VPN. No disruption.
Still hesitating about AI echo? Don't. 👇

📄: https://t.co/zUgLfHCprg

[Us2 @us2_ai]

Stop making measurements manually!

Sonographers face a real physical toll: neck pain, back pain, shoulder strain from scanning and manual measurements all day, when that time and energy could go toward what they were trained for: critical thinking, better imaging, and better patient outcomes.

https://t.co/LR5so3Qt1v and Merge built this integration specifically to give that time back.

Here's how it works:
✅ Sonographer scans the patient
✅ https://t.co/LR5so3Qt1v's FDA-cleared AI processes the echo in the background
✅ Results appear natively inside Merge Cardio, no extra clicks, no extra logins
✅ By the time the patient is seen out, the measurements are already done

Think of it like CarPlay. The AI runs seamlessly in the background, without changing how clinicians work. No new systems to learn, no extra steps. Just switch it on and the results are already there.

The result? Faster workflows. Healthier echo techs. Better patient care.

🎥 Watch the full interview with Cardiac Wire to hear how this works 👇

[Us2 @us2_ai]

#ACC26 is a wrap and what a weekend it was! 🙌

We are so grateful to our partners @Merative, @viz_ai, and @FujifilmHealth for generously hosting us at their booths throughout the conference. Being able to show our solution live to clinicians on the ground is always a highlight and this year was no exception.

A huge thank you to everyone who stopped by to learn more about what we are building. The conversations, the curiosity, and the enthusiasm from the echo community means everything to us. This is exactly why we do what we do.

The interest in AI-powered echocardiography continues to grow and weekends like this remind us just how much momentum this space has. We are grateful to be part of it.

Missed us this time? Do not fret! We will be on the road again soon. Follow us to be notified the next time we come to a city near you 🌍!

[Us2 @us2_ai]

https://t.co/LR5so3Qt1v's echocardiography AI algorithm will be integrated into a new ATTR-CM care initiative led by @Alnylam in partnership with @viz_ai !

@Alnylam is partnering with @viz_ai, the leader in AI-powered disease detection and care coordination, to develop an AI-enabled ATTR-CM care pathway designed to help clinicians identify patients earlier and guide appropriate diagnostic evaluation and referral.

The pathway combines https://t.co/LR5so3Qt1v's FDA-cleared echocardiography AI with EHR connectivity and integration into routine clinical practice to support earlier recognition of ATTR-CM and facilitate coordinated care across cardiology and heart failure teams.

We are proud that our solution will play a role in getting more patients diagnosed earlier, when it matters most.

Read the full press release: https://t.co/u7R9QZqmvH

[Us2 @us2_ai]

𝐓𝐡𝐢𝐬 𝐢𝐬 𝐰𝐡𝐚𝐭 𝐀𝐈 𝐞𝐜𝐡𝐨 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐥𝐨𝐨𝐤𝐬 𝐥𝐢𝐤𝐞 𝐰𝐢𝐭𝐡 𝐔𝐬𝟐.𝐚𝐢.

What you are seeing:
→ Every view automatically identified and classified
→ Structures traced, measurements calculated
→ Disease detection in real time
→ A full structured report. Ready. Zero clicks.

FDA cleared. CE marked. Running in clinical workflows across the world today.

Curious how our solution could elevate your echo workflow?
👉 Book a demo at https://t.co/yLoT3CRG8w

[Us2 @us2_ai]

New paper in Circulation: Cardiovascular Imaging AI detection of cardiac amyloidosis from a single routine echo view 5,776 patients. UK, Taiwan, US, Japan.

Sensitivity 88.5% | Specificity 87.2% | AUC 0.93

AI deep learning vide-based classifier outperforms the multiparametric score (0.93 vs 0.86, p<0.001).

🔗https://t.co/3yL5HXiQ8V

[Us2 @us2_ai]

🔬 𝐖𝐞’𝐯𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐞𝐧 𝐠𝐫𝐨𝐮𝐧𝐝𝐞𝐝 𝐢𝐧 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞. 𝐍𝐨𝐰 𝐢𝐭’𝐬 𝐞𝐯𝐞𝐧 𝐞𝐚𝐬𝐢𝐞𝐫 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐨𝐮𝐫𝐬.

Our upgraded Clinical Evidence page brings together the validation studies behind our software alongside the growing body of research using https://t.co/LR5so3Qt1v in clinical and scientific projects. With new filters across a wide range of topics, there’s something here for everyone, whether you’re diving into the details or simply looking to satisfy your curiosity.

A big thank you to every researcher and partner who has contributed. This page is for you too!

👉 https://t.co/glfT0wrkL1

[Us2 @us2_ai]

💡 We know that bringing new technology into a health system takes more than clinical buy-in.

That's why we've built out dedicated IT & Procurement resources on the new website, everything your technical and procurement teams need to evaluate, plan, and move forward with confidence.

We've tried to make the process as smooth as possible.

Take a look 👉 https://t.co/w2LC97GO6g

[Us2 @us2_ai]

𝐖𝐞’𝐯𝐞 𝐮𝐩𝐠𝐫𝐚𝐝𝐞𝐝 𝐭𝐡𝐞 𝐔𝐬2.𝐚𝐢 𝐰𝐞𝐛𝐬𝐢𝐭𝐞!  🎉

This is more than a refreshed look. It’s a milestone that reflects how far we’ve come and where we’re headed next.

New pages. New data. New resources. All built to showcase the real-world impact of AI-powered echo analysis.

We’ll be rolling out highlights over the next week, but if you can’t wait, go take a look now 👀

🔗: https://t.co/ET3VBkgyWo

[Us2 @us2_ai]

🫀 𝐂𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐢𝐬 𝐮𝐧𝐝𝐞𝐫𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐞𝐝 𝐁𝐔𝐓, 𝐀𝐈 𝐜𝐚𝐧 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐡𝐚𝐭.

We're proud to share our latest research published in 𝑪𝒊𝒓𝒄𝒖𝒍𝒂𝒕𝒊𝒐𝒏: 𝑪𝒂𝒓𝒅𝒊𝒐𝒗𝒂𝒔𝒄𝒖𝒍𝒂𝒓 𝑰𝒎𝒂𝒈𝒊𝒏𝒈: The development and external validation of Us2's deep learning model for automated detection of cardiac amyloidosis (CA) on echocardiography.

Trained on 4,371 patients across the UK and Taiwan, and externally validated in the US and Japan across 5,776 patients in total, the results speak for themselves:

➡️ AUC 0.93 | 88.5% sensitivity | 87.2% specificity
➡️ Robust performance across age, sex, race, amyloid subtype and echo vendor
➡️ Consistently differentiates CA from other hypertrophic phenotypes including HCM, aortic stenosis, hypertension and CKD
➡️ Full report generated in 68 𝐬𝐞𝐜𝐨𝐧𝐝𝐬

Huge thanks to our collaborators at the National Amyloidosis Centre (UCL), Duke University Health System, National Cerebral and Cardiovascular Center (Japan), and MacKay Memorial Hospital (Taiwan).

📄 Read the full paper: https://t.co/G0JlAG9cpq

📩 Contact us to learn more!

[Yoran Hummel @__YmH_]

@WarrenVsCCP At a bare minimum take the time to search for the guy’s actual name when posting about him… Joep Wennemars

[Us2 @us2_ai]

🗣️
𝐀 𝐧𝐞𝐰 #JACC 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤 𝐞𝐩𝐢𝐬𝐨𝐝𝐞 𝐡𝐚𝐬 𝐣𝐮𝐬𝐭 𝐝𝐫𝐨𝐩𝐩𝐞𝐝! Co-hosted by our co-founder @lamcardio this episode focuses on Cardiac Amyloidosis...

490 𝐝𝐚𝐲𝐬.

That is the median delay to diagnosis reported in recent data.

At the same time, mortality benefit in ATTR-CM trials emerges within 12–18 months.

The field is moving from
𝑪𝒂𝒏 𝒘𝒆 𝒅𝒊𝒂𝒈𝒏𝒐𝒔𝒆 𝒄𝒂𝒓𝒅𝒊𝒂𝒄 𝒂𝒎𝒚𝒍𝒐𝒊𝒅𝒐𝒔𝒊𝒔?
to
𝑯𝒐𝒘 𝒅𝒐 𝒘𝒆 𝒅𝒊𝒂𝒈𝒏𝒐𝒔𝒆 𝒆𝒂𝒓𝒍𝒊𝒆𝒓, 𝒂𝒏𝒅 𝒔𝒚𝒔𝒕𝒆𝒎𝒂𝒕𝒊𝒄𝒂𝒍𝒍𝒚?

At https://t.co/LR5so3Qt1v, this is exactly the problem we are building for.

𝐎𝐮𝐫 𝐀𝐈 𝐞𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐢𝐬 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐚𝐧𝐝 𝐨𝐧𝐥𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐭𝐡𝐚𝐭 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐁𝐎𝐓𝐇:
➡️ Automated, guideline-based chamber quantification and measurements
➡️ AI-driven pattern recognition

By combining standardized measurements with disease-pattern analysis, AI can help surface high-risk patients earlier.

When disease is progressive and increasingly treatable, systematic detection matters.

🎙️ Listen to the full podcast discussion!

[Yoran Hummel @__YmH_]

Bye bye to ‘RV; the forgotten chamber’, hello to automation making us better! Big win for patients with #pulmonaryHT

[Us2 @us2_ai]

𝐂𝐚𝐧 𝐅𝐮𝐥𝐥𝐲 𝐀𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐀𝐈 𝐄𝐜𝐡𝐨 𝐒𝐮𝐩𝐩𝐨𝐫𝐭 𝐏𝐮𝐥𝐦𝐨𝐧𝐚𝐫𝐲 𝐇𝐲𝐩𝐞𝐫𝐭𝐞𝐧𝐬𝐢𝐨𝐧 𝐀𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭?

A new study published in CHEST journal shows that https://t.co/LR5so3Qt1v’s fully automated AI software can reliably assess PH, providing 𝐟𝐚𝐬𝐭𝐞𝐫 𝐚𝐧𝐝 𝐦𝐨𝐫𝐞 𝐜𝐨𝐧𝐬𝐢𝐬𝐭𝐞𝐧𝐭 𝐦𝐞𝐚𝐬𝐮𝐫𝐞𝐦𝐞𝐧𝐭𝐬.

The AI was tested against expert cardiology readings and showed 𝐦𝐢𝐧𝐢𝐦𝐚𝐥 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬 in key echo measurements, including peak tricuspid regurgitation velocity (TRV), right atrial area, and tricuspid annular plane systolic excursion.

‼️ Importantly, the AI 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞𝐥𝐲 𝐝𝐞𝐭𝐞𝐜𝐭𝐞𝐝 𝐏𝐇, with performance comparable to human experts.

These results suggest that https://t.co/LR5so3Qt1v can:
✅ 𝐬𝐭𝐫𝐞𝐚𝐦𝐥𝐢𝐧�� 𝐏𝐇 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭
✅ 𝐫𝐞𝐝𝐮𝐜𝐞 𝐦𝐚𝐧𝐮𝐚𝐥 𝐰𝐨𝐫𝐤𝐥𝐨𝐚𝐝
✅ 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐦𝐨𝐫𝐞 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧-𝐦𝐚𝐤𝐢𝐧𝐠

📄 Read the full study here: https://t.co/4YTIiJ4hTB

[Us2 @us2_ai]

🔎 𝐀𝐨𝐫𝐭𝐢𝐜 𝐒𝐭𝐞𝐧𝐨𝐬𝐢𝐬 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐔𝐬2.𝐚𝐢

Aortic stenosis is one of the most common and deadly valvular heart diseases, affecting approximately 12% of people over 75, with 1 in 4 severe symptomatic patients dying within 2 years if untreated.

At https://t.co/LR5so3Qt1v, 𝐨𝐮𝐫 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐜𝐚𝐧 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐢𝐜𝐚𝐥𝐥𝐲 𝐚𝐧𝐚𝐥𝐲𝐳𝐞 𝐞𝐜𝐡𝐨 𝐢𝐦𝐚𝐠𝐞𝐬 𝐚𝐧𝐝 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐚 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐜𝐨𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧 𝐨𝐧 𝐚𝐨𝐫𝐭𝐢𝐜 𝐬𝐭𝐞𝐧𝐨𝐬𝐢𝐬 𝐬𝐞𝐯𝐞𝐫𝐢𝐭𝐲, 𝐰𝐢𝐭𝐡 𝐳𝐞𝐫𝐨 𝐡𝐮𝐦𝐚𝐧 𝐢𝐧𝐩𝐮𝐭 𝐛𝐞𝐲𝐨𝐧𝐝 𝐢𝐦𝐚𝐠𝐞 𝐚𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧.

This capability is validated in a JASE publication demonstrating fully automated AI analysis across no, mild, moderate, and severe aortic stenosis cases:👉 https://t.co/ZTWGgRtBD8

Watch this video where Dr. Hema Krishna discusses her aortic stenosis publication using the https://t.co/LR5so3Qt1v software.

💬Interested? Contact us now for a demo.